Mortality associated with the treatment of HCV with direct-acting antivirals
- PMID: 28341750
- DOI: 10.1136/gutjnl-2017-313869
Mortality associated with the treatment of HCV with direct-acting antivirals
Keywords: HEPATITIS C.
Conflict of interest statement
Competing interests: LK is a board member of Gilead. AV-P received personal fees from Gilead, BMS, Janssen, MSD, Abbvie, Roche. PS was board member of Gilead and BMS. Workshop or meeting invitation: Gilead, BMS, MSD, AbbVie, Mayoloy-Spindler, Janssen. SP was speaker for BMS, Boehringer Ingelheim, Janssen Gilead, Roche, MSD, Novartis, Abbvie; received grants from BMS, Gilead, Roche, MSD and is board member of BMS, Boehringer Ingelheim, Janssen, Gilead, Roche, MSD, Abbvie.
Comment on
-
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.Gut. 2016 Nov;65(11):1861-1870. doi: 10.1136/gutjnl-2016-312444. Epub 2016 Sep 7. Gut. 2016. PMID: 27605539 Free PMC article.